Navigation Links
O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins
Date:3/3/2008

BALTIMORE, Md., March 3 /PRNewswire/ -- Super Bowl champ O.J. Brigance, who recently confirmed a diagnosis of amyotrophic lateral sclerosis (ALS) by top doctors at The Robert Packard Center for ALS Research at Johns Hopkins, is spearheading a spring footrace organized by the Center to fund research to find a cure for the syndrome commonly known as "Lou Gehrig's Disease."

(Photo: http://www.newscom.com/cgi-bin/prnh/20080303/NEM042 )

The former Baltimore Ravens linebacker now in charge of the team's player development has assumed the role of honorary chairperson for the race, according to the Packard Center's Director Dr. Jeffrey Rothstein. Called "The Fiesta 5K & Fun Run 2008" in a salute to Cinco de Mayo celebrations that same weekend, this second annual event is planned for Saturday, May 3 at 8:00 a.m. at the Power Plant LIVE! Pavilion in Baltimore's Inner Harbor. On-line registration is now available by logging on to the Center's website, http://www.alscenter.org.

ALS is a neuromuscular disease characterized by a progressive degeneration of motor nerve cells that causes muscles to weaken, then waste away (atrophy). Intellect and the five senses remain. It crosses all socio-economic, race and ethnic lines, occurs spontaneously and has no cure. Although traditionally a disease of middle age, recent clinical observations show an increase in younger patients. This potential trend, plus evidence ALS affects military personnel at twice the rate of the general population, warrant further study.

Brigance, who is 38, has pledged to spend personal time and dollars into creating more awareness and funding for this neurodegenerative condition that affects about 30,000 Americans annually, a rate about equal to multiple sclerosis and five times that of Huntington's disease.

Says Brigance, "The Robert Packard Center for ALS Research is the only one of its kind dedicated solely to finding new therapies to slow or cure ALS. Although the Center operates within the Johns Hopkins School of Medicine in Baltimore, its scope is international. Membership is by invitation only, and it's a very elite group of international scientists working in non-traditional ways. They collaborate, rather than compete. And that's for the good of all."

According to Dr. Rothstein, "O.J. demonstrated a fighting spirit on the gridiron and he's tackling ALS the same way, with courage and a display of faith and character that are lessons to us all. We are fortunate to have him on our side and know he will use his football fame in ways that will have far- reaching effects."

Dr. Rothstein says encouraging reports about a new treatment modality pairing the bi-polar drug lithium with riluzole has come from Italian scientists who found in a 15-month clinical trial that the combination appears to slow ALS and improve breathing functions. Riluzole was developed at Johns Hopkins and is the only drug to receive FDA approval for ALS treatment.

"ALS falls into the same family of diseases as Alzheimer's and Parkinson's. It's entirely possible that funds directed to ALS research may also benefit other disease states, much in the same way that space research has yielded other discoveries, such as the creation of lightweight, heat - retaining fabrics or new food items for the home table," Dr. Rothstein says.

For more information call Emily Ehehalt a 410-516-6731 or visit http://www.alscenter.org.

Media Contacts:

Liz Chuday, 410-464-1100 or

Christen Brownlee, 410-955-7832 or cbrownlee@jhmi.edu


'/>"/>
SOURCE The Robert Packard Center for ALS Research at JohnsHopkins
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hostess(R) 100 Calorie Pack Cup Cakes Named A Most Memorable New Product of 2007
2. Anthem Blue Cross and Blue Shields Member Health Index Named BlueWorks(R) Award Winner
3. Ex-Cowboys Running Back Ron Springs Named Plaintiff in Constitutional Challenge to Texas Malpractice Award Cap
4. Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named VEGO Power Blocker
5. Greg Cleary Named Vice President, Membership Administration for Kaiser Permanente
6. Smart Balance(R) Named MVP in Refrigerated & Frozen Foods Retailer Product Lineup
7. Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today
8. Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers
9. TriWest Named Top-Level Employer of Guard, Reserve Troops
10. Michael Beland Named as OrthoSynetics(TM) Corporate Controller
11. Cell Stem Cell named Best New Journal of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
(Date:2/23/2017)... 23, 2017 According to a ... (X-ray Imaging Digital, Analog), MRI (Closed, Open), Ultrasound, CT, ... Oncology), End User (Hospitals, Imaging Centers) - Global Forecast ... global market over the forecast period of 2016 to ... Billion by 2021, at a CAGR of 6.6% from ...
Breaking Medicine Technology: